The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.
 
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
 
Steven Coutre
Consulting or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
 
Sven De Vos
Research Funding - Gilead Sciences
 
Ian Flinn
Research Funding - Gilead Sciences
 
Nina D. Wagner-Johnston
Research Funding - Gilead Sciences
 
Marshall T. Schreeder
Research Funding - Gilead Sciences
 
Jeff Porter Sharman
Research Funding - Gilead Sciences
 
Thomas E. Boyd
Research Funding - Gilead Sciences
 
Kanti Roop Rai
Research Funding - Gilead Sciences
 
John Leonard
Research Funding - Gilead Sciences
 
Bess Sorensen
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Anthony Viggiano
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Thomas Michael Jahn
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Richard R. Furman
Honoraria - Gilead Sciences; Janssen; Pharmacyclics
Consulting or Advisory Role - Gilead Sciences; Janssen Biotech; Pharmacyclics
Speakers' Bureau - Genentech; Janssen; Pharmacyclics
Research Funding - Acerta Pharma
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Pharmacyclics